🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Not all #prostatecancer BCRs are created equally!!🚨 👉Many interesting takeaways in this Swedish population-based study after prostatectomy JNCI 1⃣Half of pts w/ high-risk PCa recur within 10 years 2⃣Death from PCa at 10yr was 9% for high-risk European Association of Urology (EAU) BCR & 2.2% for

Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study out on JNCI academic.oup.com/jnci/advance-a… Study analyzed the incidence and prognostic implications of prostate-specific antigen (PSA) persistence and relapse

If you can get it (especially in 🇺🇸), can't argue with the cost of BCG: 1 yr, $1800 👇 #EAU25 debate -- Gianluca Giannarini making the point that BCG is still the best option for HR NMIBC UroToday.com Discussing European Urology paper from Scilipoti, Marco Moschini Roger Li Sarah P. Psutka MD MS

Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, Marco Moschini et al Read the full article here: buff.ly/44pcBYA #UroSoMe #MedTwitter #EurUrol #BladderCancer

🚨New in @EUPlatinum! 📌 PSMA PET for Prostate Cancer Diagnosis & Staging by Elio Mazzone et al 🧠 This comprehensive meta-analysis confirms the high diagnostic value of PSMA PET—especially when combined with MRI—but reminds us it’s not enough to skip biopsy or lymph node

🚨 New publication in European Urology Focus! 👉 Read the full article: lnkd.in/dPGbWd4Y

🚨 First-in-human study of a dual-modality PSMA-targeted probe (⁶⁸Ga-P3) for prostate cancer surgery now published in European Urology. 🔬 Combines PET/CT pre-op staging with real-time fluorescence guidance during RARP. 💡 Accuracy up to 92.3%, zero AE. Game-changer? 📖Check

📘 Just published in European Urology: 🔄 The 2025 EAU Guidelines on UTUC are here! 🧬 Major updates include: • Revised risk stratification framework • New recommendations for kidney-sparing approaches in low-risk UTUC • Clarified indications for perioperative chemotherapy &

instagram.com/reel/DLHYN95vU…

New study on Valrubicin + Docetaxel as salvage for BCG unresponsive/exposed NMIBC Eur Urol Focus Vignesh Packiam, MD 🚨 1 in 3 patients progression within 5 years. ⚠️ prostatic involvement = 2x risk of progression (p=0.02) 💢 53% adverse event rate 👎 41% recurrence-free at 3 yrs

🚨 NEW in #EuropeanUrology By Saum Ghodoussipour Roger Li Sarah P. Psutka MD MS Trinity J. Bivalacqua Joan Palou Redorta et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug

Multicenter European trial investigates gem/doce for #NMIBC. Pietro Scilipoti Ospedale San Raffaele joins Zach Klaassen Georgia Cancer Center sharing European real-world data on gem/doce for BCG-unresponsive NMIBC: 79% HG disease-free survival and 95% 1-yr PFS with excellent tolerability. A

🌍 The urologist of the future: ready for the challenge? In this Eur Urol in-press article, Stangl et al. explore how our field must evolve to meet the demands of modern medicine. Six key reflections to guide the next generation. 📝 Read more: buff.ly/9Ia1Qk4 #Urology

🚨 New in Eur Urol — In Press! 🚨 Updated systematic review & meta-analysis on the management of lower pole renal stones 🔍 PCNL offers the highest stone-free rates, ESWL fewer complications — but overall, evidence certainty remains modest. 🗞️ Read the full study:

Proud to share our new study in JNCCN! 📘 62,000+ men with nonmetastatic #ProstateCancer treated per NCCN guidelines. 🔹At 30 yrs, non-cancer deaths exceeded prostate cancer deaths—even in very high-risk men. 📎 jnccn.org/view/journals/… #JNCCN #Urology Ola Bratt

In men with nonmetastatic PCa, 30-yr mortality from PCa was lower than mortality from other causes, even among those with very high-risk disease. “Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti. urologytimes.com/view/study-sho…

Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer pubmed.ncbi.nlm.nih.gov/40639404/ In a nationwide study of over 62,000 men with nonmetastatic #ProstateCancer in Sweden🇸🇪, researchers assessed long-term mortality outcomes in patients treated according

Happy 44th birthday, Javier Zanetti! 🎂 👕 957 🏆 16 🇦🇷 143 #UCL